Psilocybin is a serotonin 2A (5-HT2A) receptor agonist that promotes neuroplasticity and alters brain network connectivity, particularly by reducing default mode network activity. Its healthspan relevance is primarily indirect, stemming from its demonstrated ability in clinical trials to produce rapid and lasting remission from mental health conditions like severe depression and PTSD, which are significant burdens on both quality of life and longevity.
Verdict
A powerful, targeted intervention for mental health, an indirect driver of healthspan.
HEALTHSPAN IMPACT
Moderate
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$2000 - $10000
Protocol
- Typically involves 1-3 macrodose sessions (e.g., 25mg) in a controlled, therapeutic setting over several months.
Flags
- Efficacy and safety are highly dependent on therapeutic 'set and setting'.
- Contraindicated for individuals with a personal or family history of psychosis (e.g., schizophrenia).
- SSRIs may blunt the subjective effects; MAOIs and lithium can cause dangerous interactions.
- Currently a Schedule I substance in the US, limiting legal access to clinical trials.